Cargando…

CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth

Classic Hodgkin lymphoma tumor cells express a functional CCR5 receptor, and tumor tissues express high CCL5 levels, suggesting that CCL5-CCR5 signaling is involved in tumor-microenvironment formation and tumor growth. Using the CCR5 antagonist, maraviroc, and a neutralizing anti-CCL5 antibody, we f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casagrande, Naike, Borghese, Cinzia, Visser, Lydia, Mongiat, Maurizio, Colombatti, Alfonso, Aldinucci, Donatella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395337/ https://www.ncbi.nlm.nih.gov/pubmed/30309853 http://dx.doi.org/10.3324/haematol.2018.196725

Ejemplares similares

In classical Hodgkin lymphoma the combination of the CCR5 antagonist maraviroc with trabectedin synergizes, enhances DNA damage and decreases three-dimensional tumor-stroma heterospheroid viability
por: Casagrande, Naike, et al.
Publicado: (2021)

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It
por: Aldinucci, Donatella, et al.
Publicado: (2019)

The CCL5/CCR5 Axis in Cancer Progression
por: Aldinucci, Donatella, et al.
Publicado: (2020)

Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma
por: Casagrande, Naike, et al.
Publicado: (2022)

In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel
por: Casagrande, Naike, et al.
Publicado: (2021)

Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
por: Aldinucci, Donatella, et al.
Publicado: (2018)

Adipose-Derived Stem Cells Primed with Paclitaxel Inhibit Ovarian Cancer Spheroid Growth and Overcome Paclitaxel Resistance
por: Borghese, Cinzia, et al.
Publicado: (2020)

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells
por: Borghese, Cinzia, et al.
Publicado: (2017)

Analogs of a Natural Peptaibol Exert Anticancer Activity in Both Cisplatin- and Doxorubicin-Resistant Cells and in Multicellular Tumor Spheroids
por: Casagrande, Naike, et al.
Publicado: (2021)

Comment on “Fibroblasts in Nodular Sclerosing Classical Hodgkin Lymphoma Are Defined by a Specific Phenotype and Protect Tumor Cells from Brentuximab-Vedotin Induced Injury” Cancers 2019, 11, 1687
por: Aldinucci, Donatella, et al.
Publicado: (2020)

The Inflammatory Chemokine CCL5 and Cancer Progression
por: Aldinucci, Donatella, et al.
Publicado: (2014)

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
por: Visser, Lydia
Publicado: (2018)

Maraviroc – A CCR5 Antagonist for the Treatment of HIV-1 Infection
por: Van Der Ryst, Elna
Publicado: (2015)

Potent In Vitro and In Vivo Anticancer Activity of New Bipyridine and Bipyrimidine Gold (III) Dithiocarbamate Derivatives
por: Altaf, Muhammad, et al.
Publicado: (2019)

Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
por: Visser, Lydia, et al.
Publicado: (2016)

New bipyridine gold(III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status
por: Altaf, Muhammad, et al.
Publicado: (2016)

New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
por: Schlecht, Hans P, et al.
Publicado: (2008)

Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
por: Lorenzen, Thore
Publicado: (2010)

Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model
por: Ochoa-Callejero, Laura, et al.
Publicado: (2013)

Stochastic Model of In-Vivo X4 Emergence during HIV Infection: Implications for the CCR5 Inhibitor Maraviroc
por: Savkovic, Borislav, et al.
Publicado: (2012)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

A randomized controlled clinical trial on the impact of CCR5 blockade with maraviroc in early infection on T-cell dynamics
por: Karris, Maile Y., et al.
Publicado: (2016)

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis
por: Le, Ngoc Dung, et al.
Publicado: (2022)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
por: López-Huertas, María Rosa, et al.
Publicado: (2017)

A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure
por: Ishihara, Yasuhiro, et al.
Publicado: (2022)

The EMILIN/Multimerin Family
por: Colombatti, Alfonso, et al.
Publicado: (2012)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
por: Ferrero, Maximiliano Ruben, et al.
Publicado: (2021)

Hodgkin Lymphoma: A Special Microenvironment
por: Opinto, Giuseppina, et al.
Publicado: (2021)

HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
por: Roche, Michael, et al.
Publicado: (2011)

In Vitro Downregulation of Matrix Metalloproteinase-9 in Rat Glial Cells by CCR5 Antagonist Maraviroc: Therapeutic Implication for HIV Brain Infection
por: Gramegna, Pasqua, et al.
Publicado: (2011)

Blocking the CCL5–CCR5 Axis Using Maraviroc Promotes M1 Polarization of Macrophages Cocultured with Irradiated Hepatoma Cells
por: Zhuang, Yuan, et al.
Publicado: (2021)

Dopamine Levels Induced by Substance Abuse Alter Efficacy of Maraviroc and Expression of CCR5 Conformations on Myeloid Cells: Implications for NeuroHIV
por: Matt, Stephanie M., et al.
Publicado: (2021)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
por: Wendt, Emily, et al.
Publicado: (2015)

Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation
por: Merino, José Joaquín, et al.
Publicado: (2020)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma
por: Bertuzzi, Clara, et al.
Publicado: (2021)

A Topical Microbicide Gel Formulation of CCR5 Antagonist Maraviroc Prevents HIV-1 Vaginal Transmission in Humanized RAG-hu Mice
por: Neff, C. Preston, et al.
Publicado: (2011)

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor
por: Jiang, Xiaowei, et al.
Publicado: (2015)

Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma, Int. J. Mol. Sci. 2016, 17, 2127
por: Sattarzadeh, Ahmad, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_20du25jlab5sv9b9go7867hrlh